Enanta Pharmaceuticals (ENTA) Receivables Refunds (2020 - 2026)

Enanta Pharmaceuticals (ENTA) has 7 years of Receivables Refunds data on file, last reported at $19000.0 in Q1 2026.

• For the quarter ending Q1 2026, Receivables Refunds fell 99.94% year-over-year to $19000.0; the trailing twelve-month figure through Mar 2026 stood at $19000.0 (down 99.94% YoY), and the FY2024 full-year result was $32.0 million, up 3.21% from the prior year.
• Receivables Refunds for Q1 2026 stood at $19000.0, down from $24000.0 in the prior quarter.
• Across five years, Receivables Refunds topped out at $33.8 million in Q1 2025 and bottomed at $19000.0 in Q1 2026.
• The 5-year median for Receivables Refunds is $28.8 million (2023), against an average of $26.3 million.
• The widest annual swing landed in 2024, when Receivables Refunds advanced 25.23%; it then sank 99.94% in 2026.
• A 5-year view of Receivables Refunds shows it stood at $28.7 million in 2022, then gained by 10.56% to $31.7 million in 2023, then grew by 2.24% to $32.4 million in 2024, then tumbled by 99.93% to $24000.0 in 2025, then fell by 20.83% to $19000.0 in 2026.
• The last three Receivables Refunds figures came in at $19000.0 (Q1 2026), $24000.0 (Q2 2025), and $33.8 million (Q1 2025), per Business Quant data.

Peer Comparison